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Cancer  patients  without  metastasis  are  generally  considered  as  candidates  for  curative  localized  radiation
therapy.  However,  while  the  beneﬁts  of  localized  radiation  have  been  demonstrated  by many  clinical
studies,  recurrences  or distant  metastases  that  develop  after  local  treatment  remain  a  major  therapeutic
challenge.  Several  in  vitro  and  in  vivo studies  have  reported  that  irradiation  may  subsequently  alter  tumor
aggression  by  reducing  or promoting  the invasiveness  of the  remaining  cancer  cells after  radiation,  which
appears  to differ  depending  on the  form  of radiation,  as  well  as  the  investigated  cell lines. Cell  lines
recapitulate  cancer  heterogeneity  based  on the  characteristics  reﬂected  in  their  genetic  abnormalities,adiation
eterogeneity
arbon ion radiotherapy
ell lines
and  thus  can  be used  as  a  tool  to investigate  the  genetic  basis  of cancer  aggression.  Importantly,  molecular
insights  into  this  process  would  allow  us  to  tailor  drug  treatments  for use  in combination  with  local
radiation  treatment.  This  review  summarizes  the  diverse  responses  of cancer  cell  invasiveness  induced
by  radiation,  and  discusses  the  possible  molecular  pathways  and  the  genetic  variations  that  may affect
radiation-altered  invasion.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Tumor metastasis is the primary cause of cancer-related death
nd accounts for more than 90% of mortalities [1,2]. Clarifying
he mechanisms of metastasis remains difﬁcult because of the
iverse effects associated with the cumulative mutations acquired
y metastatic cells and the heterogeneity of mutated genes across
etastatic cancer types. Although cell lines may  exhibit a narrow
ange of genetic variations induced by adaptation to the culture
nvironment [3], cell line-derived gene signatures can be used to
lassify the tumor from which they were derived [3–5]. Cell lines
hat maintain many of the molecular and genetic characteristics of
he parent tumor have long been used as a tool to study the bio-
ogical characteristics found in primary human tumors [6–9]. Thus,
ollections of cell lines can provide valuable information of multiple
umor types and serve as a model of tumor heterogeneity.
Radiation therapy is an effective form of cancer treatment
10,11]. In addition to conventional photon radiation, particle
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ciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
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044-579X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access
y-nc-nd/4.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
radiation therapy has been used worldwide as a novel therapeu-
tic method since the ﬁrst proposed use of protons and heavy ions
in 1946. Photon radiation deposits energy within the ﬁrst few
centimeters from the irradiated body surface, which decreases
exponentially with increasing depth [12]. In contrast, particle radi-
ation shows a unique energy deposition with a sharp increase at
the end of the particle range, which acutely diminishes beyond the
target point, thereby enabling a more accurate dose distribution
for tumor therapy compared with photon irradiation [12]. In addi-
tion, heavier particles, such as carbon ions (C-ions), exhibit higher
ionization density within individual particle tracks, which induces
signiﬁcant DNA damage and cytotoxicity in tumor cells, thereby
conferring an advantage over photon or proton irradiation in terms
of tumor-killing ability [12,13]. Several clinical studies have shown
that C-ion radiotherapy provides high local tumor control and con-
fers a great overall survival beneﬁt in many cancer types [13].
However, overcoming local recurrences or metastases that can
occur after radiotherapy remains a therapeutic challenge. While
such recurrences or metastases may  originate from micrometas-
tases present before radiation therapy, several in vitro and in vivo
studies demonstrate that therapeutic radiation can elicit cellular
changes that alter the invasiveness of cancer cells [14]. Gener-
ally, evidence indicates that photon radiation may subsequently
enhance the migration and/or invasiveness of the cancer cells
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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urviving after radiotherapy, whereas C-ion irradiation diminishes
his in several cell lines [14]. However, it should be noted that not
ll cell lines exhibit these migratory responses following irradia-
ion, as some cell lines showed reduced invasiveness after photon
adiation, or enhanced invasion after C-ion irradiation [14–16].
In order to elucidate the effects of local radiotherapy on the
haracteristics of metastatic tumors, it is fundamental to under-
tand the nature of motility utilized by the remaining cancer cells
fter radiation. Cancer cells invade either as single cells, or by mov-
ng collectively as epithelial sheets or detached clusters [17]. The
echanisms of single cell invasion are well-studied and include
wo modes of motility, mesenchymal and amoeboid (also known as
rotease-dependent and protease-independent invasion, respec-
ively) [17]. Rho GTPases serve as the master regulators of these
wo modes of motility. In addition, tumor cells alter the expres-
ion of proteases or adhesion molecules and move through the
xtracellular matrix (ECM) [17]. Thus, investigating the effects
f irradiation on the molecules regulating tumor cell invasive-
ess will further increase our understanding on the mechanisms
f radiation-induced cancer cell migration or invasion, and may
rovide a more detailed view of the complex molecular pathways
r key genetic variations to help tailor individual treatments for use
n combination with local radiotherapy.
In this review, we will initially summarize the general knowl-
dge on the molecules regulating cancer cell invasion. We  will then
eport on the diversity of cancer cell invasiveness affected by pho-
on or particle beam radiation and discuss the possible molecular
athways and genetic variations that may  affect radiation-altered
nvasion.
. Molecular principles of cancer cell invasion
.1. Mesenchymal and amoeboid modes of motility
In the ﬁrst step of metastasis, cancer cells invade into the ECM by
ynamically remodeling their intracellular cytoskeleton through
ither mesenchymal or amoeboid motility, or a combination of
oth [17–19]. Cells moving in a mesenchymal mode exhibit an
longated morphology and require the activity of proteases, such
s aspartic, cysteine, metallo, serine, and threonine proteases, to
emodel the ECM and create a path for cell migration [20–22]. The
longated cells then move through this path by forming a lead-
ng edge that extends actin-rich protrusions, such as lamellipodia,
n a Ras-related C3 botulinum toxin substrate 1 (RAC1) signaling-
ependent manner [19,23,24]. In contrast, cells using amoeboid
otility have a rounded morphology with bleb-like protrusions and
re able to squeeze through gaps between matrix proteins [19,24].
his process is mediated by actomyosin contractions, which are
ependent on Rho/Rho-associated protein kinase (ROCK) signaling,
nd occurs independently of protease activity [18,19]. However,
ome tumor-derived cell lines utilize both modes depending on the
nvironmental conditions [15,16,24], making it difﬁcult to suppress
nvasion using a single class of reagent [15,16].
.2. Rho GTPases
The Rho GTPases RAC1 and Ras homolog gene family mem-
er A (RHOA) are recognized as the masters of cell motilities and
ssential for the mesenchymal and amoeboid modes of motil-
ty, respectively [25]. Active signaling through RAC1 and RHOA
as a fundamental role in regulating cellular architecture, and is
equired for the formation of actin-rich or bleb-like protrusions,
s well as the actomyosin contractions contributing to tail retrac-
ion [25,26]. The activities of RAC1 or RHOA are tightly regulated
y guanine nucleotide exchange factors (GEF) that activate Rhoer Biology 35 (2015) 45–52
GTPases by allowing them to bind GTP, whereas GTPase-activating
proteins (GAP) inactivate Rho GTPases by enhancing GTP hydrolysis
[26]. Some GEFs and GAPs show their activity toward several Rho
GTPases, whereas others have a more restricted speciﬁcity [26]. The
molecular switch between the GTP-bound and GDP-bound forms
is observed with the cell membrane association; thus, the cyto-
solic localization of Rho GTPases is necessary to keep them in an
inactive state. As such, Rho-speciﬁc guanine nucleotide dissocia-
tion inhibitors (GDIs) sequester Rho GTPases within the cytosol to
prevent their aberrant activation [26,27]. Moreover, recent stud-
ies have shown that RAC1 and RHOA activity can also be governed
by their ubiquitin (Ub)-mediated proteasomal degradation, which
subsequently modulates the plasticity of cell migration [28,29].
2.3. Cell adhesion
Cells express variety of cell surface adhesion receptors, such as
integrins, syndecans, proteoglycans, and cadherins. Among these,
integrins are the most studied and recognized as important factors
that modulate cell migration [30]. Integrins are a family of het-
erodimeric transmembrane glycoproteins comprised of  and 
subunits. Each heterodimer consists of a large extracellular domain
capable of binding speciﬁc sequence motifs present in ECM pro-
teins, such as ﬁbronectin and collagen [30]. The binding of integrins
to their extracellular ligands promotes the formation of an intra-
cellular linkage between the integrin cytoplasmic tail and the actin
cytoskeleton through multiprotein complexes [31]. Among the
integrins, 21, 31, 51, 64 v3, and v6 are known
to play a role in cancer invasion and/or metastasis [30,32,33].
2.4. Proteases
Cells migrating via the mesenchymal mode of motility utilize the
activity of proteases to penetrate the ECM. Five human protease
classes have been classiﬁed according to catalytic mechanism:
aspartic, cysteine, metallo, serine, and threonine proteases [20–22].
These proteases interact coordinately, by activating or inhibiting
reactions, to facilitate the remodeling of the ECM [20]. For instance,
an aspartic cathepsin, cathepsin D, activates cysteine proteases
such as cathepsin B and cathepsin L. Cathepsin B proteolytically
activates other metalloproteases, such as matrix metalloproteases
(MMPs), and serine proteases [20].
Growing evidence suggests that MMPs  play clear role in tumor
metastasis and is associated with a poor prognosis [34,35]. MMPs
are a family of zinc-containing proteolytic enzymes comprised of
23 recognized members in humans [36]. Among those, MMP-1,
MMP-8, and MMP-13 are collagenases, MMP-2 and MMP-9 act
as gelatin-cleaving enzymes, and MMP-3, MMP-7, and MMP-10
degrade a broad range of ECM proteins [36]. In addition, membrane-
anchored MT1-MMP  (MMP-14) can proteolytically activate MMP-2
or MMP-13, as well as directly degrade ECM proteins – such as
type-I, -II, and -III collagen [37] – and some cell-surface proteins,
including CD44, v integrin, and syndecan 1 [38]. In addition to
the ECM degradation, some MMPs  – such as MMP-7 and MMP-28
– are capable of triggering epithelial-to-mesenchymal transition
(EMT) [39,40], a process in which epithelial cells acquire a mes-
enchymal phenotype to increase their migratory capacity [41].
Accordingly, MMP  inhibitors (MMPI) were developed as anti-
cancer agents; however, clinical trials have revealed little beneﬁt
for cancer patients in comparison to other chemotherapies, with
patients experiencing unexpected side effects of musculoskeletal
pain and inﬂammation. [42,43].Apart from MMPs, serine proteases are also prominent fac-
tors that modulate cell invasion. Among serine proteases, plasmin
promotes cellular invasion by degrading several ECM compo-
nents, such as ﬁbronectin, laminin, vitronectin, type IV collagen,
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roteoglycans, and ﬁbrin [22,44,45]. In addition, uPA enzymatically
onverts plasminogen to plasmin to potentiate cellular invasion
22]. Moreover, uPA can bind the urokinase plasminogen activator
eceptor (uPAR) in the extracellular space to induce integrin-
ependent ERK1/2 MAPK activation, which in turn stimulates
umor cell migration and invasion through myosin light-chain
inase (MLCK) phosphorylation [46]. Accordingly, a signiﬁcant
verexpression of uPA has been reported in many cancers and is
hought to be involved in tumor progression [22,47,48].
. Radiation and heterogeneity of cancer cell
igration/invasiveness
.1. Photon radiation
Numerous human cancer cell lines derived from breast [49],
entral nerve system (CNS) [49–61], colon [56,62,63], cervical
50,64,65], head and neck [66], lung [50,67–70], liver [71], pancreas
15,16,72], prostate [73], and sarcoma [59,74] were used in vitro, 2D
r 3D, or in vivo studies to examine the metastatic potentials after
hoton irradiation, and many of them showed the increased migra-
ion and/or invasion, which corresponds with a signiﬁcant increase
n the expression of pro-migratory factors including the 31 [51],
v3, v5 [55] integrins, MMP-2 [15,54,57,59], MMP-9 [59,71],
T1-MMP  [15], uPAR [52], and known inducers of EMT  [65,73].
Among those studies, Park et al. [54] reported on the diver-
ity of photon radiation-enhanced invasiveness with using four
lioblastoma cell lines, LN18, LN428, U251, and U373, and clariﬁed
he effect of phosphatase and tensin homolog (PTEN) deletion on
rradiation-induced invasion. PTEN is a tumor suppressor gene that
s frequently mutated or deleted in many tumors [75]. Speciﬁcally,
enetic PTEN alterations lead the activation of signal transduc-
ion pathways related to the tumor aggression, including elevated
I3K/AKT pathway activity via dephosphorylation of the lipid signal
ransduction molecules phosphatidylinositol 3,4,5-triphosphate
PI(3,4,5)P3) and phosphatidylinositol 3,4-biphosphate (PI(3,4)P2)
76]. In addition, PTEN mutations have been shown to enhance Rho
TPase activity and protease expression to promote the migration
nd/or invasiveness of cell lines [77–79]. Moreover, Park et al. [54]
lso determined that photon radiation enhances Src-dependent
pidermal growth factor receptor (EGFR) activation, which pro-
otes the PI3K/AKT activation and MMP-2 expression. Notably,
he PTEN mutant cell lines are unable to curtail PI3K/AKT activa-
ion, resulting in enhanced MMP-2 expression and a heightened
rradiation-induced invasive potential. In contrast, cell lines with
ild-type PTEN could effectively attenuate PI3K/AKT signaling and
MP-2 expression, and no differences were observed with respect
o cell invasion after irradiation [54]. Furthermore, the exogenous
verexpression of wild-type PTEN in mutant cell lines suppressed
hese radiation-induced effects, demonstrating that PTEN status is
n important factor for irradiation-induced invasion in glioblas-
oma [54]. Several studies have shown that the invasiveness and
MP-2 expression in U251 cells, in which the PTEN gene is mutated
80], is also enhanced after radiation [57,59]. The migration poten-
ial of U251 cells from the 3D spheroid was also increased upon
adiation [57], whereas GaMg cells, which harbor wild-type PTEN
80], showed reduced migration from the spheroid after irradiation
53]. The role of PTEN in altering cell motility was  also reported
n thyroid tumor cell lines [81,82]. PTEN-null thyroid tumor cell
ine, FTC-133 [83], exhibited the enhanced migration upon irra-
iation, which were associated with increased hypoxic inducible
actor 1 (HIF-1) activity [81]. In contrast, FTC-133 with re-
ntroduction of PTEN, or stable transfection of dominant-negative
IF-1 abrogated the radiation-induced migration [81]. It is known
hat HIF-1 involved in the radiation-induced invasiveness inr Biology 35 (2015) 45–52 47
several cancer cell lines [81,82,84,85], whose expression or activity
was affected by PTEN genetic status [81,82]. Thus, PTEN mutation
status would be prime candidate for use as a predictive marker of
radiation-altered invasiveness, and warrants further investigation.
Ras gain-of-function mutations are known to induce onco-
genesis in humans [86]. RAS proteins are the essential components
of the signaling networks controlling cell proliferation, differen-
tiation, or survival [86], and substantial evidence indicates their
involvement in cell migration and invasion [87–89]. Recently, Su
et al. [64] reported that photon radiation enhanced the migration of
the human cervical cancer cells Caski and C33A via KRAS/cRAF/p38
pathway activation. Increased localization in the lungs was also
detected after tail vein injection of irradiated-CaSki cells compared
with non-irradiated CaSki cells, in nude mice [64]. Transfection of
Caski with KRAS siRNA reduced this radiation-enhanced motility
concomitant with attenuated cRAF phosphorylation. In contrast,
irradiation had no effect on the migration, KRAS expression lev-
els, or cRAF activity in HeLa cells [64]. Accordingly, the potential
involvement of KRAS gain-of-function mutations in irradiated Caski
or C33A cells was investigated; however, no activating mutations
were detected when compared to non-irradiated counterparts
[64]. Rather, Su et al. [64] suggested that the increased cRAF
activity observed in Caski and C33A is mediated by irradiation-
induced KRAS upregulation. A recent report suggested that KRAS
requires upstream input signals to potentiate its downstream activ-
ity [90]; therefore, signals that act upstream of KRAS may  also
play an important role in its effect, as observed in tumors with
EGF-mediated KRAS activation [90]. Interestingly, EGF receptor
(EGFR) ampliﬁcation is reported in the Caski cell line that dis-
plays enhanced irradiation-induced migration [64,90], whereas
HeLa cells with normal EGFR copy numbers are devoid of this
effect [64,90]. These ﬁndings suggest that EGFR gene ampliﬁcation
could lead to increased protein expression, which may amplify its
active downstream signaling [91]. Thus, EGFR ampliﬁcation status
would also be an interesting target to determine its role in the het-
erogeneity observed with radiation-altered invasion. Nevertheless,
a separate study observed enhanced migration following photon
irradiation in HeLa cells [50]; therefore, further analysis is neces-
sary to verify the true effects of irradiation-induced invasion under
the same experimental conditions.
3.2. Heavy ion beam radiation
Although, there are not many reports studying the effects of par-
ticle radiation-altered cancer cell motility, the majority of cell lines,
which has been examined, showed reduced migration and/or inva-
siveness upon particle irradiation (Table 1). As expected, reduced
v3 and v5 integrin expression and MMP-2 expression and
activity limit the invasive potential of cells following C-ion irradia-
tion [16,55,74]. In the case of photon irradiation, several oncogenic
molecules – such as PTEN, KRAS, and EGFR – and their downstream
pathways may  play some role in modulating radiation-altered inva-
sion. Interestingly, Stahler et al. reported that C-ion irradiation
has no effect on EGFR activity and the activation of downstream
signaling effectors, including AKT and extracellular signal-related
kinases (ERK1/2). This study utilized U87 glioblastoma cells with
exogenous EGFR overexpression (U87 EGFR++) and found that
photon irradiation enhances EGFR/AKT/ERK1/2 pathway activa-
tion, which is accompanied by an increased migratory capacity
[58]. In contrast, C-ion irradiation yielded no additional effects
on pathway activation in U87 EGFR++ cells and hindered their
migration when compared to controls [58]. Thus, Stahler et al. [58]
suggested that photon irradiation may  potentiate EGFR-related
tumor cell migration, whereas C-ion irradiation may  beneﬁcially
suppress cell migration independent of EGFR-mediated signaling.
In other words, EGFR ampliﬁcation status likely has no affect on
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Table 1
Migration and invasiveness of human tumor cell lines after irradiation.
Organ Cell line Radiation Dose (Gy) (LET) Migration Invasion Key molecules Reference
CNS U87 -ray: 2, 10 + at 2 Gy N.D. v3, v5 [55]
C-ion: 0.5, 3 (91.5 ± 1.5 keV/m) − at both doses N.D.
U87 X-ray: 1, 3, 10 N.C. at all doses N.D. 3 and 1 integrin
(partial correlation)
[56]
C-ion: 1, 3, 10 − at 3, 10 Gy N.D.
U87 EGFR++ X-ray: 2, 6 + at 2 Gy, − at 6 Gy N.D. EGFR/AKT/ERK1/2 [58]
C-ion: 2, 6 (100 keV/mm)a − at both doses N.D.
LN229 EGFR++ X-ray: 2, 6 − at both doses N.D. EGFR/AKT/ERK1/2 [58]
C-ion: 2, 6 (100 keV/m)a − at both doses N.D.
SF126 X-ray: 4 N.D. + – Unpublished data
C-ion: 2 (80 keV/m)b N.D. + NOS/PI3K/AKT2/RHOA [93]
Colon HCT116 X-ray: 1, 3, 10 − at 10 Gy N.D. 1 integrin (partial
correlation)
[56]
C-ion: 1, 3, 10 − at all doses N.D.
HCT116 p21wt X-ray: 1, 3, 10 − at all doses N.D. p21 was not
affected
[63]
C-ion: 1, 3, 10 − at all doses N.D.
HCT116 p21-/- X-ray: 1, 3, 10 − at all doses N.D.
C-ion: 1, 3, 10 − at all doses N.D.
Lung A549 X-ray: 0.5, 2, 10 − at 10 Gy − at 10 Gy PI3K/AKT [67]
C-ion: 0.25, 1, 5 (50 keV/m)c − at 1, 5 Gy − at 1, 5 Gy
A549 X-ray: 0.5, 2, 10 − at 2, 10 Gy − at 10 Gy ANLN [68]
C-ion: 0.25, 1, 5 − at all doses − at 1, 5 Gy
A549 X-ray: 2, 8 + at both doses N.D. RHO [69]
C-ion: 2, 8(108 keV/m)b + at both doses N.D.
EBC-1 X-ray: 0.5, 2, 8 N.C. at all doses N.C. at all doses N.D. [68]
C-io: 0.25, 1, 4 − at 4 Gy − at 1, 4 Gy
Pancreas MIAPaCa-2 X-ray: 2, 4, 8 + at 2 Gy, - at 8 Gy + at 2, 4 Gy RHOA/RAC1,
MMP-2
[15]
C-ion: 2 (80 keV/m)b – – [16]
C-ion: 0.5, 1, 2, 4 (80 keV/mm)b − at 1, 2, 4 Gy − at 1, 2, 4 Gy [102]
AsPC-1 C-ion: 2 (80 keV/m)b – N.C. – [16]
BxPC-3 C-ion: 2 (80 keV/m)b – N.C. – [16]
Panc-1 X-ray: 2, 4, 8 N.C. at all doses + at 2, 4 Gy RHOA/RAC1, uPA/plasmin [16]
C-ion: 0.5, 1, 2, 4(80 keV/m)b − at 4 Gy + at 1, 2, 4 Gy NOS/PI3K/AKT2/RHOA/RAC1
uPA/plasmin
[16,93]
Sarcoma HT1080 X-ray: 0.5, 2, 8 + at 0.5 Gy + at 0.5, 2 Gy, - at 8 Gy aVb3 [74]
C-ion: 0.2, 1, 4 − at all doses − at all doses MMP-2
Proton: 0.5, 2, 8 − at all doses − at all doses MMP-2
+, enhanced; −, reduced; N.C., No statistically signiﬁcant change was observed; N.D., not determined.
a Dose-averaged LET.
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-ion-induced cell motility. However, further studies are required
o clarify the role of EGFR in cell migration after C-ion irradiation.
dditionally, Suetens et al. performed complementary gene expres-
ion analysis of the human prostate cancer cell line, PC3, after X-ray
r C-ion irradiation. Within the motility-related gene set, six genes
coiled-coil domain containing 88A (CCDC88A), ﬁbronectin1 (FN1),
yosin Heavy Chain 9 (MYH9), Myosin Heavy Chain 10 (MYH10),
exilin (NEXN), and Rho-associated coiled-coil containing pro-
ein kinase 1 (ROCK1) showed two- to four-fold reduction after
 Gy C-ion irradiation compared with 2 Gy X-ray irradiation [92].
urthermore, prostate cancer patients with lower FN1 expression
evels showed higher recurrence-free survival rate [92]. Therefore,
he genetic status of FN1 and the genes modulating FN1 expression,
ay  serve as a potential prognostic marker.
Several cell lines display reduced migration and invasion fol-
owing C-ion irradiation with some exceptions [16,69,93]. While
omparing the molecular changes between cell lines with different
igration/invasion responses upon irradiation could yield critical
nformation on the signaling pathways involved in radiation-
nhanced invasion, the analysis of additional cell lines is required
o gain a deeper understanding of these signaling pathways. Thus,
e used 31 tumor cell lines and one normal embryonic lung ﬁbro-
last to examine the effects of 2 Gy C-ion irradiation on cell invasion
Fig. 1). Consistent with the majority of other reports, we found that
-ion irradiation was effective in reducing the invasiveness of many
ell lines when compared to X-ray irradiation (Fig. 1). Notably, 11
ell lines showed are signiﬁcantly reduced in invasion following C-
on irradiation. However, we also conﬁrmed that a minority of celllines display enhanced invasion following C-ion irradiation, includ-
ing PANC-1 pancreatic adenocarcinoma and SF126 glioblastoma
cells (Fig. 1). The D10 values from the present study and other recent
studies (16, 94–96) (summarized in Fig. 1) indicate that the change
in invasiveness after irradiation is not associated with the radiosen-
sitivity of each cell line. Moreover, the invasive response to C-ion
irradiation occurred independent of tumor type. Interestingly, ser-
ine protease activation appeared to be involved in C-ion-enhanced
PANC-1 invasion [16], whereas nitric oxide synthase (NOS) and
PI3K inhibitors were both effective in suppressing C-ion-enhanced
PANC-1 invasion [93]. Accordingly, most of the invaded PANC-1
cells exhibited nitric oxide (NO) production and NOS/NO/PI3K/AKT
pathway activation. AKT functions to promote cell migration and
invasion through the phosphorylation of girders of actin ﬁlament
(GIRDIN), which is essential for actin organization and lamellipodia
formation [97]. Indeed, phosphorylated-GIRDIN co-localized with
phosphorylated-AKT in the lamellipodia of invaded PANC-1 cells.
Thus, it was  suggested that PANC-1 cells with C-ion irradiation-
induced NO production and elevated NOS/NO/PI3K/AKT pathway
activity have enhanced invasiveness. Consistent with the observa-
tions in PANC-1 cells, invasive SF126 cells also exhibited increased
levels of NOS and AKT, as well as enhanced AKT activation in
the lamellipodia, indicating that NOS/AKT signaling may also play
a role in SF126 invasion. Indeed, NO2− content – indicative of
the relative stability of NO – was  increased in invasive PANC-1
and SF126 cells following C-ion irradiation, whereas NO2− levels
were markedly lower in irradiated MIAPaCa-2 cells with a lower
irradiation-induced invasive potential [93].
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Fig. 1. Diversity of cancer cell invasion after irradiation. Thirty-one tumor cell lines and one normal embryonic lung ﬁbroblast line were irradiated with 4 Gy X-ray (A) or
2  Gy C-ion with a linear energy transfer value of 80 keV/m by using a mono-energetic beam with a narrow Bragg peak applied at a depth of 10 cm (B). Forty-eight hours
a n, 1 ×
9  for 24
[
h
a
h
c
f
I
F
Sfter  irradiation, cells were trypsinized and counted with trypan blue exclusion. The
6-well BME  cell invasion plates (Trevigen; Gaithersburg, MD,  USA), and incubated
16, 94–96] are indicated as a factor of radiosensitivity of the cells.
The molecular basis for these differences is unclear, although
eterogeneity in the genetic background of cell lines could be
n underlying cause. Mutations in the p53 and KRAS oncogenes
ave been identiﬁed in both PANC-1 and MIAPaCa-2 pancreatic
ells [98]; however, cell line-speciﬁc mutations in other oncogenes
rom commercially available cancer panels have not been detected.
nterestingly, whole exome sequencing and MassARRAY typing
ig. 2. Model of the molecular pathways involving the C-ion radiation-altered invasion
F126, MIAPaCa-2, AsPC-1, and BxPC-3 are summarized. 105 cells were suspended in DMEM containing 0.35% BSA, seeded onto Culture Coat
 h according to the manufacturer’s instructions (n = 3). D10 values for each cell line
analysis indicated that PANC-1 harbored a heterozygous Ser608Leu
mutation in the nitric oxide synthase 2 (NOS2) gene, whereas the
MIAPaCa-2, AsPC-1, and BxPC-3 cell lines with reduced irradiation-
induced motility all expresswild-type NOS2. Thus, further studies
are required to examine the effect of NOS2 mutations on its
molecular function and role in cell motility. Furthermore, ampli-
ﬁcation of the 19q13.1-2 chromosomal region encompassing the
. The principle molecules involved in C-ion radiation-altered invasion of PANC-1,
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Table 2
Molecules involved in the photon or C-ion radiation-altered invasiveness of MIAPaCa-2 and PANC-1 cells.
MIAPaCa-2 PANC-1
No IR X-ray (4 Gy) C-ion (2 Gy) No IR X-ray (4 Gy) C-ion (2 Gy)
Invasiveness
(Ratio vs No IR)
1 2.7 0.1 1 1.4 5.3
Modes of cell
invasion
Amobid and mesenchymal-like Amobid and mesenchymal-like
Protease MMP-2 MMP-2 MMP-2 uPA/plasmin uPA/plasmin uPA/plasmin
+  +++ −−− + n.d. +++
RhoA activation + + −−− + + +++
Rac1 activity + ++ −−− + + +
Nitric oxide
production
+ n.d. −− + n.d. +++
NOS  mRNA n.d. n.d. n.d. + n.d. ++
PI3K-AKT
activation
n.d. n.d. n.d. + n.d. ++
Mutation of gene
P53 Arg248Trp Arg273His
RAS  Gly12Cys Gly12Asp
AKT2 w ampliﬁcation
PI3K  w w
NOS1 w w
NOS2 w Ser608Leu (Ht)
+ y 25–
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RAC1 w 
, detected; ++, 1.5–2 times increase; +++, more than 2 times increase; −−, reduced b
KT2 loci has been reported in pancreatic cancer cell lines [99].
ccordingly, we demonstrated that the PANC-1 cell line used in our
tudy exhibits a 37-fold ampliﬁcation of AKT2, whereas MIAPaCa-
, AsPC-1, and BsPC-3 do not show this effect (unpublished data).
oncomitant with the genetic status, AKT2 protein levels were also
ound to be dramatically increased by 15-fold in PANC-1 cells com-
ared with MIAPaCa-2 cells (unpublished data). AKT1 and AKT2
re closely related AKT/PKB family members, yet they differ in
heir physiological roles, with AKT1 regulating proliferation and
urvival and AKT2 promoting migration and invasion [100,101].
he speciﬁc immunodetection of either activated paralog is dif-
cult due to the presence of highly conserved serine residues
102]; however, activated AKT1 and AKT2 are known to localize in
he nucleus and plasma membrane, respectively [100,102]. In our
ata, the localization of p-AKT was predominantly associated with
he plasma membrane lamellipodia with little observable nuclear
taining, implying that AKT2 was activated in invasive PANC-1 cells
93], consistent with its known function [100,101]. Therefore, AKT2
mpliﬁcation may  service as a genetic marker to predict suscepti-
ility to C-ion-altered invasiveness.
In addition, we recently reported that C-ion irradiation sup-
resses the activities of RAC1 and RHOA via ubiquitin-mediated
roteasomal degradation in MIAPaCa-2, AsPC-1, and BxPC-3 [96],
eading to lower cell motility after C-ion irradiation [16,96]. In
ontrast, RAC1 and RHOA activities were not attenuated in C-ion-
rradiated PANC-1 cells [93]. Murata et al. [69] reported that C-ion
rradiation enhances the migratory ability of A549 cells via Rho
ignal activation, as downstream MLC2 phosphorylation increased
ollowing irradiation. Thus, it would also be interesting to inves-
igate the genetic status of factors modulating RAC1 and RHOA
ctivity in future studies. We  have provided a model of the molecu-
ar pathways involving C-ion radiation-altered invasion in PANC-1,
F126, MIAPaCa-2, AsPC-1, and BxPC-3 in Fig. 2, while the responses
f principle molecules involved in radiation-altered MIAPaCa-2 or
ANC-1 invasion are summarized in Table 2.
. ConclusionIn this review, we discussed the possible molecular path-
ays and genetic variations that may  affect the heterogeneity
f radiation-altered invasiveness in cancer cell lines. Numerousw
w
50%; −−−, reduced by more than 50%; n.d., not done; w, wild type in coding region.
publications have investigated photon radiation-altered migration
and invasion; however, data on the effect of particle radiation is
still limited. Cell lines recapitulate cancer diversity, whose char-
acteristics are reﬂected in their genetic abnormalities; however,
these populations can also exhibit a narrow range of genetic vari-
ation resulting from adaptation to the culture environment. Thus,
the analysis of migration and invasion in a collection of cell lines
subjected to identical experimental conditions – including the cul-
ture environment, radiation dose, and assay timing – would provide
valuable information on multiple tumor types that could be used
as a model of the tumor variations. In this review, we  used 32
cell lines to examine the C-ion-altered invasiveness, and summa-
rized the possible molecular pathways and genetic alterations that
may  affect C-ion-altered invasion. While C-ion irradiation is mostly
effective in decreasing the invasive potential of many cancer cells,
some mutations may  potentiate an invasive phenotype in response
to irradiation. Thus, the identiﬁcation of molecular markers capable
of distinguishing these cell types would be useful to select a suit-
able concurrent therapy with C-ion radiotherapy. Nevertheless, our
results are limited to in vitro analysis; therefore, further studies are
required to conclusively examine the effect of irradiation-altered
invasion in animal models.
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